LTRN
Lantern Pharma Inc.
$3.75
+4.46%
$43.1M
No data for this timeframe.
Vol
Market Cap$43.1M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$1.5M
Inst. Activity0 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$200.0K
SEC Reports6
Recent Activity
May 15, 2026
SEC
Lantern Pharma reported Q1 2026 net loss of $3.3M ($0.30/share), a 27% YoY improvement from $4.5M ($0.42), driven by 47%
8-K — Impact 6/10
May 14, 2026
SEC
Lantern Pharma entered into a securities purchase agreement to raise approximately $4.4 million through the sale of shar
8-K — Impact 7/10
May 14, 2026
SEC
Lantern Pharma is conducting a dilutive public offering of 1,454,175 shares of common stock at $2.06 per share, plus 681
424B5 — Impact 7/10
May 12, 2026
Insider
Schalop Lee Troy bought 48,544 shares
Director @ $0.00 ($0.00)
May 12, 2026
Insider
KEYSER D JEFFREY bought 48,544 shares
Director @ $2.06 ($100.0K)
May 12, 2026
Insider
KEYSER D JEFFREY bought 48,544 shares
Director @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — EXIT
0 shares ($0.00)
Inst.
UBS Group AG — ADD
33,156 shares ($144.2K)
Price Targets
Historical data — last covering-analyst action Apr 2025. No current recommendation available.
$20.00 (Apr 2025)
Current $3.81
Low $15.00
Median $20.00
High $25.00
2 analysts
$15.00
$25.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 2, 2025 | Lake Street | INITIATE | Buy |
| Apr 25, 2024 | HC Wainwright & Co. | REITERATE | Neutral |
| Aug 10, 2023 | EF Hutton | REITERATE | Buy → Buy |
| Jun 26, 2023 | EF Hutton | MAINTAIN | Buy → Buy |
| May 18, 2023 | HC Wainwright & Co. | INITIATE | Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.38 | $-0.38 — $-0.38 | 5% YoY | 1 |
| Next Q | $-0.38 | $-0.38 — $-0.38 | 3% YoY | 1 |
| Current FY | $-1.51 ▲ +3.8% | $-1.51 — $-1.51 | 4% YoY | 1 |
| Next FY | $-2.02 | $-2.02 — $-2.02 | -34% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $334.5K | — |
| WELLS FARGO & COMPANY/MN | $4.5K | TRIM |
| MORGAN STANLEY | $1.8K | — |
| BANK OF AMERICA CORP | $21.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Schalop Lee | BUY | $0.00 |
| May 12, 2026 | KEYSER D | BUY | $100.0K |
| May 12, 2026 | KEYSER D | BUY | $0.00 |
| May 12, 2026 | Schalop Lee | BUY | $100.0K |
5 institutional holders with $1.5M total value (496,524 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, WELLS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 384,041 | $1.2M | 77.3% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 110,400 | $334.5K | 22.2% | — |
| 3 | WELLS FARGO & COMPANY/MN | 1,475 | $4.5K | 0.3% | TRIM -65.4% |
| 4 | MORGAN STANLEY | 601 | $1.8K | 0.1% | — |
| 5 | BANK OF AMERICA CORP /DE/ | 7 | $21.00 | 0.0% | NEAR_EXIT -92.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | EXIT | 16,041 | 0 | -100.0% | $0.00 | 2025-Q4 |
| UBS Group AG | ADD | 24,653 | 33,156 | +34.5% | $144.2K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 16,041 | — | $69.8K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 4,986 | 1,725 | -65.4% | $7.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 77 | 6 | -92.2% | $26.00 | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 42,787 | 18,400 | -57.0% | $65.1K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 16,545 | 0 | -100.0% | $0.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 8,008 | 4,608 | -42.5% | $14.7K | 2024-Q4 |
2 unique insiders with 4 transactions. Net insider value: $200.0K ($200.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Schalop Lee Troy | Director | BUY | 48,544 | $0.00 | $0.00 |
| May 12, 2026 | KEYSER D JEFFREY | Director | BUY | 48,544 | $2.06 | $100.0K |
| May 12, 2026 | KEYSER D JEFFREY | Director | BUY | 48,544 | $0.00 | $0.00 |
| May 12, 2026 | Schalop Lee Troy | Director | BUY | 48,544 | $2.06 | $100.0K |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 1 mixed, 1 neutral. Avg impact: 6.5/10.
MIXED
8-K
6/10
Lantern Pharma reported Q1 2026 net loss of $3.3M ($0.30/share), a 27% YoY improvement from $4.5M ($
May 15, 2026
BEARISH
8-K
7/10
Lantern Pharma entered into a securities purchase agreement to raise approximately $4.4 million thro
May 14, 2026
BEARISH
424B5
7/10
Lantern Pharma is conducting a dilutive public offering of 1,454,175 shares of common stock at $2.06
May 14, 2026
BEARISH
8-K
7/10
Lantern Pharma reported Q4 2025 earnings with net loss per share of $-0.36, in-line with consensus,
Apr 21, 2026
NEUTRAL
8-K
5/10
Lantern Pharma demonstrated its withZeta.ai AI platform, discussing its capabilities, market opportu
Apr 10, 2026
BEARISH
424B5
7/10
Lantern Pharma is conducting a best-efforts common stock offering to raise capital, following its re
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Apr 2025. No current recommendation available.
$20.00 mean target (Apr 2025)
$15.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $3.81 |
| Target Low | $15.00 |
| Target Mean | $20.00 |
| Target Median | $20.00 |
| Target High | $25.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.38 | $-0.38 | $-0.38 | 5.0% | +0.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.38 | $-0.38 | $-0.38 | 2.6% | +0.0% | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.51 | $-1.51 | $-1.51 | 3.8% | +3.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-2.02 | $-2.02 | $-2.02 | -33.8% | +0.0% | — | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.380 | |
| 7d ago | $-0.380 | |
| 30d ago | $-0.380 | |
| 60d ago | $0.000 | -0.380 |
| 90d ago | $0.000 | -0.380 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 2, 2025 | Lake Street | INITIATE | — | Buy |
| Apr 25, 2024 | HC Wainwright & Co. | REITERATE | — | Neutral |
| Aug 10, 2023 | EF Hutton | REITERATE | Buy | Buy |
| Jun 26, 2023 | EF Hutton | MAINTAIN | Buy | Buy |
| May 18, 2023 | HC Wainwright & Co. | INITIATE | — | Neutral |
| Mar 21, 2023 | EF Hutton | REITERATE | — | Buy |
| Feb 15, 2023 | EF Hutton | MAINTAIN | — | Buy |
| Nov 1, 2022 | EF Hutton | INITIATE | — | Buy |
| Mar 11, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 2, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Oct 7, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jul 28, 2020 | Colliers Securities | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 15, 2026
earnings_calendar
LTRN Q1 2026 Earnings Scheduled — 2026-05-15
May 13, 2026
earnings_calendar
LTRN Q1 2026 Earnings Scheduled — 2026-05-13
May 5, 2026
earnings_calendar
LTRN Q1 2026 Earnings Scheduled — 2026-05-05
Apr 2, 2026
short_volume
Short Volume: LTRN — 57.1% short (0.4M / 0.6M)
Short: 360,181 | Exempt: 11,728 | TRF Vol: 630,284 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_volume
Short Volume: LTRN — 58.1% short (0.4M / 0.7M)
Short: 422,518 | Exempt: 8,672 | TRF Vol: 726,657 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: LTRN — 60.9% short (4.9M / 8.1M)
Short: 4,943,023 | Exempt: 40,503 | TRF Vol: 8,120,723 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
LTRN Q4 2025 Earnings After Market Close — 2026-03-30
Mar 30, 2026
short_volume
Short Volume: LTRN — 73.1% short (1.2M / 1.6M)
Short: 1,188,343 | Exempt: 89,197 | TRF Vol: 1,626,457 | Short Ratio: 73.1% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: LTRN — 62.9% short (1.0M / 1.6M)
Short: 975,054 | Exempt: 47,130 | TRF Vol: 1,550,359 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
Mar 5, 2026
earnings_calendar
LTRN Q4 2025 Earnings After Market Close — 2026-03-05